Oblenio Bio is a biotechnology company developing trispecific T-cell engager (TCE) therapies for autoimmune diseases. The company raised a $62M Series B led by Pfizer Ventures in 2026 to advance its lead candidate LBL-051, a trispecific TCE targeting BCMA, CD19, and CD20 for B-cell driven autoimmune disorders.
Company Info
Clinical Development Pipeline
Recent News
Oblenio Bio raises $62M Series B led by Pfizer Venture Investments to advance LBL-051, a trispecific TCE targeting BCMA, CD19, and CD3, into first-in-human trials for autoimmune disease.
Leadership Team
Chief Executive Officer
Careers & Job Openings